Verastem's GFH375 trial data at ASCO 2025 shows a 52% response rate in pancreatic cancer and no dose-limiting toxicities ...

Shares of Verastem Oncology (VSTM) dropped 19% on Monday despite the company announcing positive updated data from the dose ...

As of 10:44:41 AM EDT. Market Open. BOSTON, June 02, 2025--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway ...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced ...

New dose-escalation data from Verastem Oncology’s phase I/II cancer study in China prompted the company to say it was ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

It was back in October of 2022 when Verastem (NASDAQ:VSTM) updated investors on their RAMP clinical trials, which included their recurrent low-grade serous ovarian cancer “LGSOC”, KRAS G12V ...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today the ...

Verastem (VSTM) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one ...

Verastem (VSTM) closed the last trading session at $6.40, gaining 18.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall ...

Verastem, Inc. (NASDAQ:VSTM) recently announced that the FDA has accepted their NDA for accelerated approval for the combination of avutometinib and defactinib “recurrent low-grade serous ...

BOSTON, June 02, 2025--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive ...